stockportfolio.pro
Stocks / AXGN vs BCRX
AXGN vs BCRX
Axogen, Inc. and BioCryst Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Axogen, Inc. (AXGN) | BioCryst Pharmaceuticals, Inc. (BCRX) | |
|---|---|---|
| Market cap | $2.2B | $2.1B |
| Revenue (latest FY) | $225.21M | $874.84M |
| Net income (latest FY) | $-15.70M | $263.86M |
| Revenue growth (5y CAGR) | 14.9% | 117.9% |
| Net margin | -7.0% | 30.2% |
| Return on equity | -12.2% | -221.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AXGN — free Open BCRX — freeFrequently asked questions
Which is bigger, AXGN or BCRX?
Axogen, Inc. is larger by market capitalization — $2.2B versus $2.1B.
Which grows faster, AXGN or BCRX?
Over the last five fiscal years, BioCryst Pharmaceuticals, Inc. grew revenue faster — 117.9%/yr versus 14.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.